Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early treatment of COVID-19 pneumonia with glucocorticoids
2020-001827-15Phase 3Active
- Sponsor
- Navarrabiomed
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of methylprednisolone in coronavirus pneumonia (2 arms), sponsored by Navarrabiomed. Primary endpoint: Treatment failure up to 14 days. Started May 2020; status: active.
02
Drugs
methylprednisolone
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001827-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001827-15.